STOCK TITAN

Clearside Biomedical to Participate in Two Upcoming Investor Conferences in June 2021

Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Neutral)
Tags
conferences
Rhea-AI Summary

Clearside Biomedical (NASDAQ:CLSD) announced participation in two investor conferences in June 2021. George Lasezkay, CEO, and Thomas A. Ciulla, Chief Medical Officer, will host fireside chats at:

  • JMP Securities Life Sciences Conference: June 16, 2021, at 1:00 pm ET
  • Raymond James Human Health Innovations Conference: June 23, 2021, at 8:40 am ET

Live and archived webcasts can be found on the company's website. Clearside specializes in treatments for serious eye diseases using its proprietary SCS Microinjector technology.

Positive
  • None.
Negative
  • None.

ALPHARETTA, Ga., June 09, 2021 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (NASDAQ:CLSD), a biopharmaceutical company dedicated to developing and delivering treatments that restore and preserve vision for people with serious back of the eye diseases, announced today that George Lasezkay, Pharm.D., J.D., President and Chief Executive Officer, and Thomas A. Ciulla, M.D., MBA, Chief Medical Officer and Chief Development Officer, will participate in two upcoming investor conferences in June 2021:

JMP Securities Life Sciences Conference
Fireside Chat
Wednesday, June 16, 2021 at 1:00 pm ET

Raymond James Human Health Innovations Conference
Fireside Chat
Wednesday, June 23, 2021 at 8:40 am ET

A link to the live and archived webcasts may be accessed on the Clearside website under the Investors section: Events and Presentations. An archive of the webcast will be available for three months.

About Clearside Biomedical

Clearside Biomedical, Inc. is a biopharmaceutical company dedicated to developing and delivering treatments that restore and preserve vision for people with serious back of the eye diseases. Clearside’s proprietary SCS Microinjector® targets the suprachoroidal space (SCS®) and offers unique access to the macula, retina and choroid where sight-threatening disease often occurs. The Company’s SCS injection platform is an inherently flexible, in-office, non-surgical procedure, intended to provide targeted delivery to the site of disease and to work with both established and new formulations of medications. For more information, please visit www.clearsidebio.com.

Investor and Media Contacts:

Jenny Kobin
Remy Bernarda
ir@clearsidebio.com
(678) 430-8206

Source: Clearside Biomedical, Inc.


FAQ

When is the JMP Securities Life Sciences Conference for Clearside Biomedical?

The JMP Securities Life Sciences Conference for Clearside Biomedical is on June 16, 2021, at 1:00 pm ET.

What date is Clearside Biomedical participating in the Raymond James Human Health Innovations Conference?

Clearside Biomedical will participate in the Raymond James Human Health Innovations Conference on June 23, 2021, at 8:40 am ET.

Where can I find the webcasts for Clearside Biomedical's investor conferences?

Webcasts for Clearside Biomedical's investor conferences can be accessed on their website under the Investors section.

Who are the executives participating in the investor conferences for Clearside Biomedical?

George Lasezkay, President and CEO, and Thomas A. Ciulla, Chief Medical Officer, will participate in the investor conferences.

What is the focus of Clearside Biomedical's treatments?

Clearside Biomedical focuses on developing treatments for serious back of the eye diseases.

Clearside Biomedical, Inc.

NASDAQ:CLSD

CLSD Rankings

CLSD Latest News

CLSD Stock Data

66.74M
70.22M
7.39%
23.17%
2.35%
Biotechnology
Pharmaceutical Preparations
Link
United States of America
ALPHARETTA